Ferroptosis-centered Disease Response Information

General Information of the Disease (ID: DIS00124)
Name
Osteonecrosis
ICD
ICD-11: FB81
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
In total 2 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [1]
Responsed Disease Bisphosphonates-related osteonecrosis of jaw [ICD-11: FB81]
Responsed Drug Zoledronic acid Investigative
 Drug Info 
Responsed Regulator F-box only protein 9 (FBXO9) Suppressor
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model RAW 264.7 cells Leukemia Mus musculus CVCL_0493
Response regulation FBXO9 was downregulated in Zoledronic acid-treated osteoclast and promoted osteoclasts ferroptosis by inhibiting FBXO9 -mediated p53 ubiquitination and degradation. The study provided a possible theoretical target for the clinical treatment of Bisphosphonates (BPs)-related osteonecrosis of jaw (BRONJ).
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [1]
Responsed Disease Bisphosphonates-related osteonecrosis of jaw [ICD-11: FB81]
Responsed Drug Zoledronic acid Investigative
 Drug Info 
Responsed Regulator Cellular tumor antigen p53 (TP53) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model RAW 264.7 cells Leukemia Mus musculus CVCL_0493
Response regulation FBXO9 was downregulated in Zoledronic acid-treated osteoclast and promoted osteoclasts ferroptosis by inhibiting FBXO9-mediated p53 ubiquitination and degradation. The study provided a possible theoretical target for the clinical treatment of Bisphosphonates (BPs)-related osteonecrosis of jaw (BRONJ).
References
Ref 1 Zoledronic acid promotes osteoclasts ferroptosis by inhibiting FBXO9-mediated p53 ubiquitination and degradation. PeerJ. 2021 Dec 16;9:e12510. doi: 10.7717/peerj.12510. eCollection 2021.